Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
Dr. Reddy’s Laboratories Ltd is a global pharmaceutical company that aims to make medicines more approachable. Founded in 1984 by Dr. Kallam Anji Reddy, the company has its headquarters in Hyderabad, Telangana, India. Dr. Reddy’s is known for producing medicines that target a range of therapeutic areas. The company is committed to making high-quality medicines. They develop, manufacture, and sell a variety of pharmaceutical products. These include active pharmaceutical ingredients (APIs), generics, biosimilars, and over-the-counter (OTC) products. Their medicines can treat issues related to cardiovascular health, diabetes, oncology, and dermatology. Read More...
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 28,905.40 | 25,725.20 | 22,029.60 | 19,338.90 | 18,137.60 |
Total Expenses | 21,719.10 | 19,713.70 | 19,038.50 | 16,503.40 | 16,308 |
Profit Before Tax | 7,201 | 6,048.50 | 3,061.40 | 2,883.50 | 1,885.70 |
Profit After Tax | 5,577.90 | 4,507.30 | 2,182.50 | 1,951.60 | 2,026 |
Operating Profit after Depreciation | 7,357.40 | 6,154.30 | 3,086.90 | 2,932.50 | 1,927.90 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 10,493.90 | 9,274 | 8,135.30 | 8,816.90 | 7,949 |
Total Non Current Assets | 14,058.50 | 11,859.60 | 11,964.60 | 12,066.50 | 10,626.20 |
Total Current Assets | 24,805.30 | 20,425.50 | 17,782.30 | 14,550.30 | 12,599.10 |
TOTAL ASSETS | 38,863.80 | 32,285.10 | 29,746.90 | 26,616.80 | 23,225.30 |
Total Shareholder's Fund | 28,254.80 | 23,286.10 | 19,212.40 | 17,641.70 | 15,598.80 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 4,543.30 | 5,887.50 | 2,810.80 | 3,570.30 | 2,984.10 |
Net Cash used in Investing Activities | -4,034.20 | -4,108.70 | -2,565.40 | -2,254.70 | -494.80 |
Net Cash used in Financing Activities | -376.30 | -2,686.10 | -242.20 | -29.80 | -2,515.90 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 20,346.10 | 17,553.80 | 14,887.20 | 14,150.20 | 12,593.60 |
Total Expenses | 14,554.80 | 13,687.80 | 12,663.40 | 11,094 | 9,817.80 |
Profit Before Tax | 5,791.30 | 3,866 | 2,223.80 | 3,056.20 | 2,775.80 |
Profit After Tax | 4,342 | 2,612.80 | 1,623.20 | 2,186.40 | 2,937.70 |
Operating Profit after Depreciation | 5,813.10 | 3,882.90 | 2,261.80 | 3,102.90 | 2,823.60 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 7,628.20 | 7,220.60 | 6,164.40 | 5,868 | 4,461.60 |
Total Non Current Assets | 12,543.40 | 11,586.50 | 11,004.30 | 10,685.40 | 9,369.10 |
Total Current Assets | 17,815.90 | 13,788.30 | 13,491.30 | 10,944.20 | 10,106.70 |
TOTAL ASSETS | 30,359.30 | 25,374.80 | 24,495.60 | 21,629.60 | 19,475.80 |
Total Shareholder's Fund | 24,240.80 | 20,474.20 | 18,336.20 | 16,983.70 | 15,191.90 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 3,449.70 | 5,052.90 | 1,338.70 | 3,514.20 | 1,839.20 |
Net Cash used in Investing Activities | -3,428.70 | -3,403.20 | -1,990.10 | -1,453.60 | -1,689.20 |
Net Cash used in Financing Activities | 68.10 | -2,696.90 | 505.50 | -794.30 | -224.10 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 8,381.20 | 8,038.20 | 7,696.10 | 7,113.80 | 7,236.80 |
Total Expenses | 6,108.20 | 5,961.70 | 5,566.20 | 5,282.60 | 5,213.70 |
Profit Before Tax | 1,874.30 | 1,917.40 | 1,882.60 | 1,605.20 | 1,829.10 |
Profit After Tax | 1,404.20 | 1,341.90 | 1,392.40 | 1,309.80 | 1,380.90 |
Operating Profit after Depreciation | 2,427.40 | 2,390.10 | 2,323 | 2,032.20 | 2,242 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 5,015 | 6,696.30 | 5,841.20 | 5,104.80 | 4,103 |
Total Expenses | 3,822.60 | 3,974.70 | 3,888.20 | 3,726.20 | 3,446.70 |
Profit Before Tax | 1,119.40 | 2,640.80 | 1,913.90 | 1,339.20 | 631.90 |
Profit After Tax | 849.40 | 1,882.10 | 1,417.20 | 1,034.80 | 475.20 |
Operating Profit after Depreciation | 1,427.80 | 2,929.20 | 2,170.80 | 1,591.30 | 883.90 |
₹40/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Dr Reddys Laboratories Ltd | ₹1,211.80 | ₹1,01,115.50 |
Sun Pharmaceuticals Industries Ltd | ₹1,699.75 | ₹4,07,826.96 |
Divis Laboratories Ltd | ₹5,949.15 | ₹1,57,931.24 |
Cipla Ltd | ₹1,452.70 | ₹1,17,322.09 |
Torrent Pharmaceuticals Ltd | ₹3,104.95 | ₹1,05,080.90 |
Mankind Pharma Ltd | ₹2,451.35 | ₹1,01,134.59 |
Dr Reddys Laboratories Ltd is quoting at Rs 1241.5, up 1.14% on the day as on 12:49 IST on the NSE. The stock is up 0.45% in last one year as compared to a 7.61% jump in NIFTY and a 18.78% jump in the Nifty Pharma index.
06 Feb 2025, 01:06 pm
Dr Reddys Laboratories Ltd is quoting at Rs 1176.75, down 0.38% on the day as on 13:19 IST on the NSE. The stock jumped 0.73% in last one year as compared to a 7.43% rally in NIFTY and a 20.58% spurt in the Nifty Pharma index.
29 Jan 2025, 01:35 pm
Dr Reddy's Laboratories reported 2.4% increase in consolidated net profit to Rs 1,413.70 crore in Q3 FY25 compared with Rs 1,380.90 crore in Q3 FY24.
24 Jan 2025, 10:45 am
24 Jan 2025, 08:31 am
27 Dec 2024, 06:12 pm
View More